Paperpal Prime Logo

Cardiovascular Drugs and Therapy : Impact Factor & More

eISSN: 1573-7241pISSN: 0920-3206

Key Metrics

CiteScore
5.6
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
0.93
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Cardiovascular Drugs and Therapy

Cardiovascular Drugs and Therapy Journal Specifications

Overview
Publisher SPRINGER
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1987
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Cardiovascular Drugs and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Cardiovascular Drugs and Therapy

Interpreting Short-Term Safety and Albuminuria in the FINE-TURK Registry.
  • 23 Oct 2026
  • Cardiovascular drugs and therapy
Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.
  • 17 Oct 2026
  • Cardiovascular drugs and therapy
MiR‑18a‑5p Serves as a Diagnostic and Prognostic Biomarker and Attenuates Hypoxia‑Induced Cardiac Microvascular Endothelial Injury by Targeting the HIF1A/NF‑κB Pathway in Chronic Heart Failure.
  • 15 Oct 2026
  • Cardiovascular drugs and therapy
Rethinking Plaque Stabilization with Evolocumab in Diabetes: Methodological Considerations from the YELLOW III Trial.
  • 14 Oct 2026
  • Cardiovascular drugs and therapy
MSCs-derived Exosomal miRNA-335-5p Alleviates Apoptosis and Inflammation in Myocardial Infarction by Inhibiting BCL2L11.
  • 14 Oct 2026
  • Cardiovascular drugs and therapy
Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights
  • 9 Oct 2026
  • Cardiovascular Drugs and Therapy
Interpreting Short-Term Safety and Albuminuria in the FINE-TURK Registry.
  • 23 Oct 2026
  • Cardiovascular drugs and therapy
Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.
  • 17 Oct 2026
  • Cardiovascular drugs and therapy
MiR‑18a‑5p Serves as a Diagnostic and Prognostic Biomarker and Attenuates Hypoxia‑Induced Cardiac Microvascular Endothelial Injury by Targeting the HIF1A/NF‑κB Pathway in Chronic Heart Failure.
  • 15 Oct 2026
  • Cardiovascular drugs and therapy
Rethinking Plaque Stabilization with Evolocumab in Diabetes: Methodological Considerations from the YELLOW III Trial.
  • 14 Oct 2026
  • Cardiovascular drugs and therapy
MSCs-derived Exosomal miRNA-335-5p Alleviates Apoptosis and Inflammation in Myocardial Infarction by Inhibiting BCL2L11.
  • 14 Oct 2026
  • Cardiovascular drugs and therapy
Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights
  • 9 Oct 2026
  • Cardiovascular Drugs and Therapy

FAQs on Cardiovascular Drugs and Therapy